Cargando…
pⅢ期非小细胞肺癌中miR-155的表达
BACKGROUND AND OBJECTIVE: Despite undergoing curative resection, the 5-year survival rate for stage Ⅲ non-small cell lung cancer (NSCLC) patients is less than 25%. There is a need for biomarkers for prediction of survival and guiding individual therapy. MiR-155 is one of most commonly upregulated mi...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000445/ https://www.ncbi.nlm.nih.gov/pubmed/24854560 http://dx.doi.org/10.3779/j.issn.1009-3419.2014.05.10 |